Clearbridge BioMedics raises USD7.2M Series B from Vertex Venture, others

Clearbridge BioMedics, Singapore-based medical tech company, has today announced a new series B venture round of SGD 9M (USD 7.2M). Vertex Venture Holdings, a wholly owned venture capital arm of Temasek Holdings, is the lead investor.

The startup’s flagship product is the ClearCell System, which consists of patent-pending CTChips that are able to detect, isolate, and retrieve tumor cells from blood samples obtained from patients. The isolated tumor cells can then be stained for identification and analysis. Read more

Singapore’s ClearBridge BioMedics wins 2012 Asian Entrepreneurship Awards

Clearbridge BioMedics has won the 2012 Asian Entrepreneurship Awards in a business plan competition held from 9-11th May 2012 in Kiashiwanoha, Japan.

The company won due to its ClearCell System, a cell-based invitro diagnostic device that isolates and retrieves intact and viable circulating tumor cells from blood.

It was the only Singaporean participant out of 18 total startup companies representing 12 countries. As the winner, it took home three million yen (S$47,000) and three years of free tenancy at the Tokatsu Techno Plaza in Chiba Prefecture. Read more

Singapore tech incubator Clearbridge Accelerator gets investment from Silicon Valley VC

Clearbridge Accelerator, a Singapore-based technology incubator that focuses on biomedical devices, nanotech, advanced material sciences and computational algorithms, has received an investment from Tim Draper, founder and managing director of venture capital firm Draper Fisher Jurvetson, according to a press release. Read more